A new analysis highlights the potential of vitamin D in reducing colorectal cancer (CRC) risk, with some studies suggesting it could cut the risk by half. However, researchers caution that the evidence is complex and contradictory.
The Promise of Vitamin D
Low vitamin D levels have long been associated with a higher risk of developing colorectal cancer. One large study involving over 12,000 participants found that people with low blood levels of vitamin D had a 31% greater risk of CRC compared to those with higher levels. Another study reported a 25% lower risk among individuals with high dietary vitamin D intake.
Data from the Nurses' Health Study, a long-term investigation of American nurses, showed that women with the highest vitamin D intake had a 58% lower risk of developing colorectal cancer compared to those with the lowest intake.
The Biological Mechanism
Vitamin D is synthesised in the skin in response to sunlight and exerts its effects through vitamin D receptors (VDRs) found throughout the body, including in colon tissue. When activated, these receptors help regulate gene activity related to inflammation, immune response, and cell growth – processes central to cancer development.
Preclinical studies have shown that the active form of vitamin D (calcitriol) can suppress inflammation, boost immune surveillance, inhibit tumour blood vessel growth, and regulate cell division.
Mixed Results from Trials
Despite promising observational data, randomised controlled trials (RCTs) have produced inconsistent outcomes. The VITAL trial, involving over 25,000 participants, found no significant reduction in overall colorectal cancer incidence with 2,000 IU/day of vitamin D supplementation over several years.
However, a meta-analysis of seven RCTs showed a 30% improvement in CRC survival rates with vitamin D supplements, suggesting potential benefits later in the disease course. On the other hand, the Vitamin D/Calcium Polyp Prevention Trial found no reduction in adenoma recurrence, raising questions about who benefits most.
Interpreting the Evidence
The discrepancies highlight the importance of considering the totality of evidence. Biologic plausibility is strong, and observational studies suggest a meaningful link, but clinical evidence is not yet strong enough to recommend vitamin D as a standalone prevention or treatment strategy.
Maintaining sufficient vitamin D levels – at least 30 ng/mL – is a low-risk, cost-effective health measure. When combined with regular screening, a healthy diet, physical activity, and personalised care, vitamin D could play a valuable role in overall cancer prevention.
Vitamin D is not a miracle cure, but it is part of a broader picture. Its role in colorectal cancer is promising but still being defined. For now, focusing on evidence-based lifestyle changes, regular screenings, and staying informed as new research unfolds remains the best approach.
